M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...
The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results